diethylnitrosamine has been researched along with mebendazole in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ghanim, AMH; Saber, S; Younis, NS | 1 |
1 other study(ies) available for diethylnitrosamine and mebendazole
Article | Year |
---|---|
Mebendazole augments sensitivity to sorafenib by targeting MAPK and BCL-2 signalling in n-nitrosodiethylamine-induced murine hepatocellular carcinoma.
Topics: Alanine Transaminase; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cyclin D1; Diethylnitrosamine; Hep G2 Cells; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Liver Neoplasms; Male; MAP Kinase Signaling System; Matrix Metalloproteinase 2; Mebendazole; Mice; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Signal Transduction; Sorafenib; Tissue Inhibitor of Metalloproteinase-1; Tumor Burden; Vascular Endothelial Growth Factor A | 2019 |